Krystal Biotech, Inc. (KRYS)

Market Cap	4.70B
Revenue (ttm)	241.52M
Net Income (ttm)	52.37M
Shares Out	28.76M
EPS (ttm)	1.77
PE Ratio	92.42
Forward PE	34.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	186,044
Open	159.20
Previous Close	160.83
Day's Range	159.20 - 165.96
52-Week Range	107.50 - 219.34
Beta	0.80
Analysts	Strong Buy
Price Target	206.67 (+26.55%)
Earnings Date	Nov 4, 2024

About KRYS

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cys...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: KRYS
• Website: https://www.krystalbio.com

Analyst Forecast

According to 7 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price forecast is $206.67, which is an increase of 26.55% from the latest price.

Price Target

$206.67

(26.55% upside)

Analyst Consensus: Strong Buy